Sales & Marketing

Sales & Marketing

The latest pharmaceutical sales and marketing news

Boston Scientific Fined $42m Over Patent InfringementBoston Scientific Fined $42m Over Patent Infringement
Boston Scientific Fined $42m Over Patent Infringement

Following a five-year legal battle between Boston Scientific and TissueGen, Boston Scientific has had to pay $42m

Mar 6, 2023 Sales & Marketing
Garuda Therapeutics Closes Series B Funding With $62mGaruda Therapeutics Closes Series B Funding With $62m
Garuda Therapeutics Closes Series B Funding With $62m

Garuda Therapeutics has announced that it has closed series B funding with $62m

Mar 6, 2023 Sales & Marketing
AbbVie Expects 37% Decline In Humira Sales Following New Biosimilars Hitting The US MarketAbbVie Expects 37% Decline In Humira Sales Following New Biosimilars Hitting The US Market
AbbVie Expects 37% Decline In Humira Sales Following New Biosimilars Hitting The US Market

AbbVie has announced that it expects a 37% decline in sales of Humira following the approval of biosimilars

Mar 6, 2023 Sales & Marketing
Moderna Agrees First Acquisition For $85mModerna Agrees First Acquisition For $85m
Moderna Agrees First Acquisition For $85m

After a pivotal few years, Moderna has agreed its first acquisition, worth $85m, which will allow the company access to cell-free DNA synthesis and amplification technologies. Moderna is set to acquire OriCiro Genomics K.K., gaining its expertise in DNA synthesis and amplification.

Feb 1, 2023 Sales & Marketing
Astrazeneca Set To Buy Cincor For $1.8bnAstrazeneca Set To Buy Cincor For $1.8bn
Astrazeneca Set To Buy Cincor For $1.8bn

AstraZeneca has announced that it is set to acquire the clinical-stage biopharmaceutical company CinCor in a deal worth up to $1.8bn.

Feb 1, 2023 Sales & Marketing
Cost Of Over 350 Drugs Expected To Increase In 2023Cost Of Over 350 Drugs Expected To Increase In 2023
Cost Of Over 350 Drugs Expected To Increase In 2023

With many pharma companies preparing for President Joe Biden’s Inflation Reduction Act (IRA) to begin having an impact, and inflation continuing to soar, the cost of at least 350 drugs is expected to rise in the US throughout 2023.

Feb 1, 2023 Sales & Marketing
Astrazeneca To Acquire Neogene For Up To $320mAstrazeneca To Acquire Neogene For Up To $320m
Astrazeneca To Acquire Neogene For Up To $320m

AstraZeneca announces acquisition of Neogene

Dec 1, 2022 Sales & Marketing
Siemens Healthineers And Atrium Health Team Up In $140m DealSiemens Healthineers And Atrium Health Team Up In $140m Deal
Siemens Healthineers And Atrium Health Team Up In $140m Deal

Simiens Healthineers and Atrium Health announce partnership deal

Dec 1, 2022 Sales & Marketing
Full-Life Technologies To Acquire Focus-X TherapeuticsFull-Life Technologies To Acquire Focus-X Therapeutics
Full-Life Technologies To Acquire Focus-X Therapeutics

Focus-X Therapeutics develops targeted radiopharmaceuticals to treat cancer, based on proprietary peptide engineering technology. This technology involves peptide radioliglands which precisely deliver alpha or beta emitters to break down cancer cell DNA. It allows for high-quality optimisation of peptide radioligland vectors for key pharmaceutical attributes such as biodistribution, binding affinity, and in vivo stability.

Dec 1, 2022 Sales & Marketing
Merck Supports Orna’s Development Of Orna Vaccine And Therapeutics ProgrammesMerck Supports Orna’s Development Of Orna Vaccine And Therapeutics Programmes
Merck Supports Orna’s Development Of Orna Vaccine And Therapeutics Programmes

A collaboration effort has been agreed between Merck Research Laboratories (MSD) and Orna Therapeutics to discover, develop, and commercialise programmes of engineered circular (oRNA) therapies, in areas including infectious diseases and oncology.

Oct 27, 2022 Sales & Marketing
Pfizer Buys Global Blood Therapeutics For $5.4 BillionPfizer Buys Global Blood Therapeutics For $5.4 Billion
Pfizer Buys Global Blood Therapeutics For $5.4 Billion

Global Blood Therapeutics (GBT), a rare disease pharmaceutical company, has been bought by Pfizer for $5.4 billion in cash. The purchase will give Pfizer ownership of Oxbryta, a sickle cell disease-fighting drug which generated $195 million in 2021, with Pfizer expecting an increase in profits when it’s introduced to the global market.

Oct 27, 2022 Sales & Marketing
Kelai Pharmaceutical Partners With Nutrasource To Support Drug Development Into Natural CompoundsKelai Pharmaceutical Partners With Nutrasource To Support Drug Development Into Natural Compounds
Kelai Pharmaceutical Partners With Nutrasource To Support Drug Development Into Natural Compounds

US-based Kelai Pharmaceutical has hired Canada-based full service contract research organisation (CRO), Nutrasource Pharmaceutical and Nutraceutical Providers, to assist with their early stage drug growth programme, where they hope to establish drug candidates from botanical crops to develop prescribed drugs.

Oct 27, 2022 Sales & Marketing